Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Shares Climb 6% – Still a Buy?

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) shot up 6% during mid-day trading on Thursday. The company traded as high as $35.34 and last traded at $35.34. 109,317 shares were traded during trading, a decline of 45% from the average session volume of 197,988 shares. The stock had previously closed at $33.34.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Raymond James Financial reissued a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Thursday. Morgan Stanley began coverage on Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, October 20th. They set an “equal weight” rating and a $26.00 target price for the company. UBS Group upgraded Lakefront Biotherapeutics American Depositary Shares to a “buy” rating in a research report on Wednesday, September 23rd. Royal Bank Of Canada raised shares of Lakefront Biotherapeutics American Depositary Shares from a “sector perform” rating to an “outperform” rating and lifted their price target for the company from $26.00 to $45.00 in a research note on Wednesday, September 23rd. Finally, Weiss Ratings raised shares of Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, October 2nd. Three analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Lakefront Biotherapeutics American Depositary Shares currently has a consensus rating of “Hold” and an average price target of $35.50.

Lakefront Biotherapeutics American Depositary Shares Trading Up 2.5%

The company has a fifty day moving average of $30.16 and a 200-day moving average of $29.95. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of -24.25 and a beta of 0.22.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last announced its earnings results on Wednesday, November 11th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The business had revenue of $7.87 million for the quarter. As a group, equities research analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -1.26 EPS for the current year.

Institutional Investors Weigh In On Lakefront Biotherapeutics American Depositary Shares

Large investors have recently made changes to their positions in the stock. Alps Advisors Inc. purchased a new position in Lakefront Biotherapeutics American Depositary Shares during the third quarter worth approximately $2,617,000. Commonwealth Equity Services LLC acquired a new position in Lakefront Biotherapeutics American Depositary Shares in the third quarter valued at approximately $279,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares during the 1st quarter worth about $248,000. Finally, ABC Arbitrage SA acquired a new position in Lakefront Biotherapeutics American Depositary Shares in the first quarter valued at about $382,000. 32.46% of the stock is currently owned by hedge funds and other institutional investors.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.